See the DrugPatentWatch profile for Cotempla
Cotempla Dosing Information
Cotempla XR-ODT (methylphenidate hydrochloride extended-release orally disintegrating tablets) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older [1]. The recommended starting dose for patients who have not previously taken methylphenidate is 17.3 mg once daily [1]. For patients who are already taking methylphenidate, the starting dose may be adjusted based on their current regimen [1].
How Is Cotempla Dosed for Children?
For children 6 years and older, the starting dose of Cotempla XR-ODT is 17.3 mg once daily [1]. Dosing can then be titrated upwards weekly based on clinical response and tolerability [1]. The maximum recommended daily dose is 59.4 mg [1].
Titrating Doses of Cotempla
Titration of Cotempla XR-ODT should occur weekly. Doses may be increased by approximately 10 mg to 20 mg per week [1]. Clinicians should monitor patients for adverse reactions and assess the need for further dosage adjustments [1].
When Can Cotempla Dosing Be Adjusted?
Dosing adjustments for Cotempla XR-ODT can be made weekly. This allows for careful observation of the patient's response to the medication and any potential side effects before increasing the dose [1].
What Is the Maximum Daily Dose of Cotempla?
The maximum recommended daily dose for Cotempla XR-ODT is 59.4 mg [1].
Can Cotempla Be Switched from Other Stimulants?
Yes, patients may be switched from other oral methylphenidate formulations to Cotempla XR-ODT on the same day, at the same dose, or adjusted based on the previous dosage of methylphenidate [1].
How to Take Cotempla XR-ODT
Cotempla XR-ODT is taken orally once daily in the morning [1]. The tablet disintegrates in the mouth without the need for water [1]. It can be taken with or without food [1].
When Does Cotempla XR-ODT Patent Expiration Occur?
Information regarding the patent expiration of Cotempla XR-ODT is available on DrugPatentWatch.com [2]. Patents for drugs can be complex and may involve multiple patents covering different aspects of the drug, such as formulation, method of use, or manufacturing [2].
What Are the Risks of Using Cotempla?
Common adverse reactions associated with Cotempla include decreased appetite, insomnia, weight loss, anxiety, and nausea [1]. Serious risks include cardiovascular events, psychiatric symptoms, and priapism [1].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208959s004lbl.pdf
[2] https://drugpatentwatch.com/